findmyKOL
Clinical trialNCT01639872CompletedPhase 4Interventional

Clozapine for Cannabis Use in Schizophrenia

SponsorDartmouth-Hitchcock Medical CenterEnrollment49Cannabis AbuseCannabis DependenceDual DiagnosisSchizophrenia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Many individuals with schizophrenia also suffer from marijuana addiction that worsens their problems related to schizophrenia. Most of the medications prescribed for schizophrenia have no effect on reducing marijuana use. Preliminary data suggests that clozapine, an atypical antipsychotic, may limit marijuana use in people diagnosed with schizophrenia, but it is not commonly used due to its side effects and is reserved for people who do not respond to other antipsychotic medications. In the proposed study, 132 individuals who are diagnosed with both schizophrenia and a cannabis use disorder will be randomized to a 12-week treatment course with either clozapine or risperidone (another commonly prescribed antipsychotic medication) to test the hypothesis that patient treated with clozapine will have decreased cannabis use as compared to patients treated with risperidone. Should this study indicate that clozapine will lessen marijuana use in persons diagnosed with schizophrenia more than risperidone, it will provide evidence needed to begin to shift clinical practice toward its use in this population.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Cns Network Inc

    Garden Grove, California, United States

  • Pacific Research Partners

    Oakland, California, United States

  • University of Miami

    Miami, Florida, United States

  • Unversity of Massachusetts Medical School

    Worcester, Massachusetts, United States

  • Michigan State University / Cherry Street Health Services

    Grand Rapids, Michigan, United States

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire, United States

  • University of North Carolina/unc Center for Excellence in Community Mental Health

    Raleigh, North Carolina, United States

  • University of South Carolina

    Columbia, South Carolina, United States

  • Rutland Regional Medical Center

    Rutland, Vermont, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 May 2013
Primary completion
29 Mar 2017
Completion
29 Mar 2017
Last update posted
5 May 2020
Registered enrollment
49
Registry id
NCT01639872

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.